Sanofi (Three molecules)

Sanofi (Three molecules) Overview

Status Acquired/​Merged
Latest Deal Type Asset Purch.
Financing Rounds 1

Sanofi (Three molecules) General Information

Description

A Portfolio of three molecules. The three molecules are IXA-001, IXA-002, and IXA-003. IXA-001 is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, IXA-002 is an MAO A-B inhibitor while IXA-003 is an MAO B inhibitor.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Primary Office
  • 54, rue La Boétie
  • 75008 Paris
  • France
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sanofi (Three molecules) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sanofi (Three molecules)‘s full profile, request access.

Request a free trial

Sanofi (Three molecules) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sanofi (Three molecules)‘s full profile, request access.

Request a free trial